학술논문
Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement.
Document Type
Article
Author
Source
Subject
*CENTRAL nervous system
*BRUTON tyrosine kinase
*T cells
*CEREBROSPINAL fluid
*MANTLE cell lymphoma
*IMMUNE reconstitution inflammatory syndrome
*
*
*
*
*
Language
ISSN
1042-8194
Abstract
This document presents a case series of four patients with relapsed mantle cell lymphoma (MCL) and central nervous system (CNS) involvement who were treated with a combination of bridging therapy, CAR-T cell therapy (BA), and Bruton's tyrosine kinase inhibitors (BTKi). The patients showed remission of CNS disease after BA, with a complete response rate of 75%. The use of BTKi as bridging therapy and maintenance treatment following BA was found to be effective and safe, with no severe side effects reported. These findings suggest that this treatment approach may be a promising option for patients with relapsed MCL and CNS involvement. [Extracted from the article]